Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/27/2008WO2008012089A3 Polyphenol/peptide composition and use thereof for promoting gastric health
03/27/2008WO2008011560A3 Benzothiophene inhibitors of rho kinase
03/27/2008WO2008010934A3 Triazolyl phenyl benzenesulfonamides
03/27/2008WO2008009924A3 Indoles useful in the treatment of inflammation
03/27/2008WO2008008854A9 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
03/27/2008WO2008008660A3 Cyclopentane derivatives as antiglaucoma agents
03/27/2008WO2008008541A3 Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
03/27/2008WO2008008431A3 Heteroaryl sulfonamides and ccr2/ccr9
03/27/2008WO2008007098A3 Drug delivery polymer with hydrochloride salt of clindamycin
03/27/2008WO2008006895A3 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
03/27/2008WO2008006511A3 Use of fosfluridine tidoxil (ft) for the treatment of intraepithelial proliferative diseases
03/27/2008WO2008005869A3 Infant formulas for early brain development
03/27/2008WO2008005651A3 Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
03/27/2008WO2008005489A3 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
03/27/2008WO2008004001A3 The use of pvp to control the release profile of an active ingredient from a hydrophilic polymer matrix tablet
03/27/2008WO2008002674A3 Bicyclic compositions and methods for modulating a kinase cascade
03/27/2008WO2008002671A3 Metalloprotease inhibitors
03/27/2008WO2008002655A3 Crystalline forms of atorvastatin
03/27/2008WO2008002594A8 Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
03/27/2008WO2008000469A3 Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom
03/27/2008WO2008000070B1 Glycyrrhetinic acid derivatives
03/27/2008WO2007150011A3 Prolyl hydroxylase inhibitors
03/27/2008WO2007149550A3 Modulation of differentiation and cell function via fox01 and notch signaling
03/27/2008WO2007147525A3 Fbpase co-crystals
03/27/2008WO2007146006A3 Sustained release oxycodone composition with acrylic polymer and a surfactant
03/27/2008WO2007143096A3 Compounds for treating cancers
03/27/2008WO2007141200A8 Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases
03/27/2008WO2007140317A3 Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
03/27/2008WO2007139984A3 Duloxetine hcl polymorphs
03/27/2008WO2007139812A3 Novel silicone film former for delivery of actives
03/27/2008WO2007138232A3 Use of granisetron for the treatment of sub-types of rosacea, and pharmaceutical compositions containing same
03/27/2008WO2007136668A9 N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
03/27/2008WO2007136573A3 Antidiabetic bicyclic compounds
03/27/2008WO2007135538A3 Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives
03/27/2008WO2007135530A3 Pharmaceutically & veterinarily suitable salt
03/27/2008WO2007135026A3 Substituted pteridines as therapeutic agents
03/27/2008WO2007133790A3 NF-ϰB INHIBITORS AND USES THEREOF
03/27/2008WO2007133747A3 PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN
03/27/2008WO2007132296A3 Multilayer tablet
03/27/2008WO2007132179A3 Therapeutics comprising pyridinium derivatives
03/27/2008WO2007130589A3 Nl, n4-bis (buta-i, 3-dienyl) butane-i, 4-diamine pharmaceutical compositions and uses thereof
03/27/2008WO2007128480A3 Thioglycosides as pharmaceutically active agents
03/27/2008WO2007127711A3 Abnormal cannabidiols as agents for lowering intraocular pressure
03/27/2008WO2007127212A3 Anti-viral agents that activate rnase l
03/27/2008WO2007122510A3 Asymmetric membranes for drug delivery devices
03/27/2008WO2007122400A3 Novel polypeptides and use thereof
03/27/2008WO2007122369A3 Novel tumour suppressor
03/27/2008WO2007119098A3 Use of an nmda receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
03/27/2008WO2007105015A3 DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
03/27/2008WO2007103370A3 Quinazoline derivatives as phosphodiesterase 10 inhibitors
03/27/2008WO2007095341A3 Sterilization of corticosteroids with reduced mass loss
03/27/2008WO2007095316A3 Compositions and methods for oligonucleotide formulations
03/27/2008WO2007094513A3 Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
03/27/2008WO2007092879A3 Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
03/27/2008WO2007089318A3 Compositions and methods for reducing food cravings
03/27/2008WO2007084314A3 MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
03/27/2008WO2007082178A3 Prostaglandin reductase inhibitors
03/27/2008WO2007079221A3 Method for treating dry-eye syndrome
03/27/2008WO2007072060A3 Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
03/27/2008WO2007071958A3 Combination of zd6474 and pemetrexed
03/27/2008WO2007071394A3 Combination of a 5-ht4 agonist with a cholinesterase inhibitor
03/27/2008WO2007071363A3 METHODS OF USING THE CALCINEURIN A VARIANT Cnaβ1
03/27/2008WO2007070820A3 Method for preparing 4-demethyldaunorubicin
03/27/2008WO2007066151A3 Topical compositions for treatment of respiratory disorders
03/27/2008WO2007057508A3 Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
03/27/2008WO2007056163A3 Aminopyrimidines useful as kinase inhibitors
03/27/2008WO2007045663A3 Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
03/27/2008WO2007038829A8 Method of drug design
03/27/2008WO2007036717A8 4- (4-BROMO-2-FLUOROANILINO) -6-METHOXY-7- (l-METHYLPIPERIDIN-4 -YLMETHOXY) QUINAZOLINE MONOHYDRATE
03/27/2008WO2007020411A8 Amide derivatives
03/27/2008WO2006125621A8 Substituted piperidines as renin inhibitors
03/27/2008WO2006102604A3 Topical formulations of borinic acid antibodies and their methods of use
03/27/2008WO2006052880A8 Synergistic effects of combined administration of mirtazapine and a stimulant compound
03/27/2008WO2005117971A3 Regulators of angiogenesis
03/27/2008WO2004066943A3 Methods for diagnosis anf monitoring of neurological disease by detection of an encephalotoxin
03/27/2008WO2000071079A3 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
03/27/2008US20080077372 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
03/27/2008US20080076943 4-(Hydroxymethyl)-2,6-dimethoxyphenylboronic acid chemical intermediate for preparing corticotropin-releasing factor receptor antagonists
03/27/2008US20080076921 Inhibitors of bruton's tyrosine kinase
03/27/2008US20080076836 Method and apparatus for using light to enhance cell growth and survival
03/27/2008US20080076834 administering a combination of erythritol and glycerin; moisterizers; psoriasis and keratoderma;
03/27/2008US20080076831 applying chlorhexidine or chlorhexadine and a topical carrier; relieves pain and itching
03/27/2008US20080076829 N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyano-3-fluorophenoxy)-2-hydroxy-2-methylpropanamide; muscle wasting disease; bone-related disease
03/27/2008US20080076828 Substituted acylanilides and methods of use thereof
03/27/2008US20080076827 Treatment of Inflammatory Bowel Disease
03/27/2008US20080076826 alpha, beta, and gamma types; beta3-adrenaline receptor stimulative action; storage stability
03/27/2008US20080076825 with levodopa and decarboxylase inhibitors; Parkinson's syndrome; from Knoevenagel condensation of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyanoacetamide
03/27/2008US20080076824 Compounds That Inhibit Replication Of Human Immunodeficiency Virus
03/27/2008US20080076823 Methods of improving bone health and muscle health
03/27/2008US20080076821 Applying curcumin ester prodrugs to the nasal cavity; nasal administration enhances the effectiveness of curcumin in the brain and reduce side effects associated with liver metabolism
03/27/2008US20080076820 Improving the activities of daily living in a post-stroke patient by administering nefiracetam or its salts initiated within 12 months of stroke; nefiracetam possesses neurotrophic activity
03/27/2008US20080076819 Treating non-insulin dependent diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome; 6-[(1-cycloheptyl-4,4-dimethyl-5-oxopyrrolidin-3-yl)methoxy]nicotinonitrile for example
03/27/2008US20080076818 Novel processes for the preparation of dpp iv inhibitors
03/27/2008US20080076817 Neurotrophic N-glyoxyl-prolyl ester compounds e.g. 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate; non-immunosuppressive; side effect reduction; neurodegenerative diseases
03/27/2008US20080076816 Non-Covalent Complexes Comprising Carbon Nanotubes
03/27/2008US20080076815 Sulfonamide or sulfonimide functional indazole or indole compounds such as N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydryoxyethyl]phenyl]methanesulfonamide; diabetes, obesity, hyperlipidemia and urinary incontinence
03/27/2008US20080076814 Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators
03/27/2008US20080076813 Benzene, Pyridine, and Pyridazine Derivatives
03/27/2008US20080076812 Lyophilized powder includes an antioxidant, a buffer and a bulking agent; storage stability; improved stability upon reconstitution; treating endothelin-mediated disorders such as hypertension
03/27/2008US20080076811 Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
1 ... 3322 3323 3324 3325 3326 3327 3328 3329 3330 3331 3332 3333 3334 3335 3336 3337 3338 3339 3340 3341 3342 ... 7860